MarketPeel
Insider Trading Intelligence
Pricing
…
GJ

Gary S. Jacob

CRDF
DIRECTOR · CARDIFF ONCOLOGY, INC. · CIK 0001266802
FILING MIX · LIFETIME100%/0%
BUYS
13
SELLS
0
TOTAL VALUE
$104.6K
COMPANIES
2
ACTIVE SINCE
May 2020
HOLDINGS NOW
188,526
AVG SELL PX
—
TRADE KIND
SHOWING 13 / 13
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Gary S. Jacob, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+25.00%-3.13%+2.56%-5.69%-10.97%—
14d4+25.00%+7.40%+5.50%+1.90%-6.75%—
30d4+25.00%+3.02%+3.20%-0.18%-18.46%—
60d4+25.00%+33.69%+5.63%+28.06%-28.38%—
90d4+25.00%+52.21%+11.44%+40.77%-30.75%—
180d4+25.00%+252.43%+13.20%+239.24%-41.87%—
1y4+25.00%+73.34%+22.18%+51.16%-76.82%—
2y4+0.00%-57.47%+23.35%-80.81%-88.62%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CRDF · 76,106 shares · as of Jun 10, 2021
019,02738,05357,08076,1062021SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 13 buys / 0 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
OKYO
OKYO PHARMA LTD
PURCHASEGRANT
Stock grant
3,500$1.40$4.9K112,420Jul 21, 2026Jul 23, 2026 ↗View →
OKYO
OKYO PHARMA LTD
PURCHASE
Chief Executive Officer
12,500$4.00$50.0K12,500May 19, 2022May 19, 2022 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
755——76,106Jun 10, 2021Jun 15, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
530——76,106Jun 10, 2021Jun 15, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
223——76,106Jun 10, 2021Jun 15, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
44,734——76,106Jun 10, 2021Jun 15, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
218——76,106Jun 10, 2021Jun 15, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
28,858——76,106Jun 10, 2021Jun 15, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
293——76,106Jun 10, 2021Jun 15, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
1,900$10.42$19.8K21,452Mar 23, 2021Mar 23, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
470$10.40$4.9K21,922Mar 23, 2021Mar 23, 2021 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
28,858——76,106Jun 17, 2020Jun 19, 2020 ↗View →
CRDF
CARDIFF ONCOLOGY, INC.
PURCHASE
17,483$1.43$25.0K19,552May 14, 2020May 18, 2020 ↗View →
Other insiders · CRDF
Loading peer insiders…
About this filer
CIK 0001266802
ROLE
Director
PRIMARY
CRDF
COMPANIES
2
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001266802DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback